Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,999.00
Bid: 1,997.00
Ask: 1,998.00
Change: 34.00 (1.73%)
Spread: 1.00 (0.05%)
Open: 1,991.00
High: 2,028.00
Low: 1,983.00
Prev. Close: 1,965.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 14th Feb 2013 08:09

African Barrick Gold: Deutsche Bank cuts target price from 410p to 340p, while staying with its hold recommendation. Investec reduces target price from 405p to 315p and downgrades from buy to hold. JP Morgan lowers target price from 370p to 290p and downgrades to underweight.AG Barr: Barclays downgrades to equal-weight. Canaccord Genuity downgrades to hold with a target price of 490p.ASOS: HSBC raises target price from 2750p to 3530p and upgrades to overweight.Barclays: Deutsche Bank revises target price from 360p to 380p maintaining a buy recommendation. Investec moves target price from 320p to 340p, while downgrading from buy to hold.Brown (N) Group: HSBC takes target price from 420p to 430p reiterating an overweight rating.Britvic: Barclays cuts to equal-weight. JP Morgan lowers target price from 400p to 380p and downgrades to underperform.Daily Mail and General Trust: UBS raises target price from 520p to 650p maintaining a neutral rating.Euromoney Institutional Investor: UBS increases target price from 775p to 900p and retains a neutral rating.FlyBe: HSBC lowers target price from 80p to 70p and retains an overweight rating.Gulfsands Petroleum: Cantor Fitzgerald (formerly Seymour Pierce) reduces target price from 366p to 162p and keeps a buy recommendation.G4S: Investec revises target price from 280p to 330p and upgrades from hold to buy.Halma: Investec increases target price from 515p to 550p keeping a buy recommendation.Hikma: Panmure Gordon ups target price from 825p to 930p, while leaving its buy recommendation unchanged.JSC Bank of Georgia Holdings: Citigroup downgrades to neutral with a target price of 1500p.Laird: JP Morgan moves target price from 281p to 291p reiterating an overweight rating. Numis increases target price from 250p to 310p and stays with its buy recommendation.McBride: Investec shifts target price from 150p to 154p and maintains a buy rating.Morgan Crucible: Investec ups target price from 295p to 370p and leaves its buy recommendation unchanged.Newmark Security: Cantor Fitzgerald (formerly Seymour Pierce) moves target price from 1.50p to 2.00p maintaining a buy recommendation.Next: HSBC increases target price from 4100p to 4965p upgrading to overweight.Norcros: Numis downgrades to add with a target price of 20p.Oxford Instruments: JP Morgan takes target price from 1500p to 1750p and leaves its overweight rating unchanged.Reckitt Benckiser: Deutsche Bank ups target price from 4600p to 4800p and stays with its buy recommendation. Credit Suisse raises target price from 3700p to 4000p retaining a neutral rating. Nomura increases target price from 4800p to 4900p, while its buy recommendation is kept. Oriel Securities moves target price from 3730p to 4700p upgrading to add.Rolls-Royce Group: Investec downgrades from buy to add with its target price at 1005p.Salamander Energy: Investec revises target price from 200p to 250p and upgrades from hold to buy.SOCO International: Exane BNP lowers target price from 405p to 390p, while leaving its neutral rating unaltered.Spirent Communications: Panmure Gordon shifts target price from 184p to 192p and keeps a buy recommendation.SVG Capital: Oriel Securities shifts target price from 360p to 370p, while its buy recommendation is kept.Synergy Health: Investec raises target price from 1048p to 1105p, while downgrading from buy to add.Telecity Group: Investec ups target price from 750p to 1000p and upgrades from hold to buy. UBS revises target price from 945p to 1000p reiterating a buy recommendation.Tullow Oil: Deutsche Bank reduces target price from 1105p to 1075p keeping a hold recommendation. Credit Suisse cuts target price from 1450p to 1350p, while its neutral rating remains unchanged. Nomura lowers target price from 1350p to 1330p and retains a reduce rating.Whitbread: Investec increases target price from 1650p to 2000p, but still recommends selling.
More News
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more
30 Apr 2021 17:01

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

Read more
30 Apr 2021 08:58

TOP NEWS: Hikma Pharma confident after promising start to year

TOP NEWS: Hikma Pharma confident after promising start to year

Read more
30 Apr 2021 07:57

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

Read more
30 Apr 2021 07:38

Hikma predicts generics revenue at top of guidance

(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.

Read more
23 Apr 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
21 Apr 2021 12:08

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

Read more
21 Apr 2021 10:06

Hikma resumes asthma drug launch, Vectura pays special dividend

Hikma resumes asthma drug launch, Vectura pays special dividend

Read more
21 Apr 2021 09:01

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

Read more
21 Apr 2021 07:52

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

Read more
21 Apr 2021 07:30

Hikma resumes US launch of 'Advair Diskus' generic

(Sharecast News) - Hikma Pharmaceuticals has resumed the launch of its generic version of GlaxoSmithKline's 'Advair Diskus' in the United States, it announced on Wednesday, following Food and Drug Administration (FDA) approval of an amendment it submitted to its Abbreviated New Drug Application in January.

Read more
19 Apr 2021 16:02

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.